Compare NICE Ltd (NICE) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NICE Ltd vs Twist Bioscience Corp — how do they compare? NICE Ltd trades at $101.98 (market cap $5.99B), while Twist Bioscience Corp trades at $123.01 (market cap $7.82B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals.
| NICE | TWST | |
|---|---|---|
Market Cap | $5.99B | $7.82B |
Sector | Technology | Health |
52-Week High | $153.44 | $124.88 |
52-Week Low | $83.15 | $24.16 |
Enterprise Value | $5.72B | $7.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NICE stock trades at $101.85, up 4.88% today, showing strong momentum after exceeding Q2 2026 earnings expectations with $2.70 EPS versus $2.63 expected. The company maintains solid fundamentals with 65.12% gross margins and 13.86% net income margin, while technical indicators show bullish momentum with key resistance at $103. Recent partnerships with RingCentral and ESG initiatives highlight strategic growth positioning.
The outlook remains positive with analyst consensus target of $115 suggesting 13% upside potential. Key risks include competitive pressures in customer engagement software and potential margin compression as revenue growth outpaces profit growth. Institutional ownership trends show mixed activity with some firms increasing positions while others trim holdings.
Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
